Gubra A/S Logo

Gubra A/S

CRO & biotech accelerating peptide drug discovery for metabolic and fibrotic diseases.

GUBRA | CO

Overview

Corporate Details

ISIN(s):
DK0062266474
LEI:
254900T17RRFZONO6W53
Country:
Denmark
Address:
Hørsholm Kongevej 11 B, 2970 Hørsholm
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Gubra A/S is a specialized preclinical Contract Research Organization (CRO) and biotechnology company focused on peptide-based drug discovery for metabolic and fibrotic diseases, such as obesity, diabetes, and MASH. Founded in 2008, the company operates through two primary business areas: CRO Services, providing advanced preclinical research to accelerate partners' drug development, and Discovery & Partnerships, which develops its own pipeline of next-generation peptide therapeutics. Gubra leverages its expertise in in vivo pharmacology and peptide chemistry to streamline and advance early-stage drug development for its clients and internal projects.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Gubra A/S filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Gubra A/S

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Gubra A/S via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Noile-Immune Biotech Inc. Logo
Developing PRIME technology-enhanced CAR-T cell immunotherapies for treating solid tumors.
Japan 4893
NRGene Technologies Ltd. Logo
AI-powered genomic analysis software to accelerate and optimize plant and animal breeding.
Israel NRGN
Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea 244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea 382150

Talk to a Data Expert

Have a question? We'll get back to you promptly.